Wegovy Lawsuit 2026: MDL Status, Claims & Compensation

Quick Answer
– What it is: Thousands of plaintiffs allege Novo Nordisk failed to adequately warn that Wegovy (semaglutide) causes severe gastrointestinal injuries including gastroparesis, bowel obstruction, and pancreatitis.
– Who qualifies: People who used Wegovy and were diagnosed with gastroparesis, intestinal obstruction, cyclic vomiting syndrome, pancreatitis, or required hospitalization for related complications.
– What it may be worth: Compensation estimates in active pharmaceutical mass torts of this complexity typically range from $100,000 to $500,000+ for severe injury cases, depending on medical documentation, treatment costs, and injury permanence, though no Wegovy-specific settlement fund has been publicly announced as of early 2026.

Case Snapshot

Introduction

The Wegovy lawsuit has grown into one of the most closely watched pharmaceutical mass torts in the United States. Novo Nordisk, the Danish drugmaker behind Wegovy and Ozempic, faces thousands of federal claims alleging it knew, or should have known, that semaglutide carries a serious risk of gastrointestinal injury well beyond what its labeling disclosed.

MDL No. 3094 is now consolidated before Judge Karen S. Marston in the Eastern District of Pennsylvania. The litigation spans two parallel legal tracks: personal injury claims from patients who suffered physical harm, and consumer fraud claims from patients who argue they would not have taken the drug had they received proper warnings.

Something similar worth reading: AI Lawsuit News 2026: Cases, Claims, Who Qualifies

What makes this case unusual is scale. Wegovy and Ozempic together generated over $13 billion in global revenue for Novo Nordisk in 2023. That commercial dominance translates into a large exposed population and a defendant with formidable litigation resources.

As of early 2026, discovery is active. Bellwether cases are being shaped. Anyone who took Wegovy and suffered a qualifying injury needs to understand where this case stands before filing deadlines begin to close.

What Is the Wegovy Lawsuit?

The Wegovy lawsuit refers to the growing body of federal personal injury and consumer protection claims filed against Novo Nordisk over serious gastrointestinal complications allegedly caused by Wegovy (semaglutide injection, 2.4 mg).

The central legal theory is failure to warn. Plaintiffs allege Novo Nordisk knew from clinical trial data that semaglutide significantly slows gastric motility. They argue the company did not adequately disclose that risk in its FDA-approved labeling, leaving prescribing physicians and patients without the information needed to make informed treatment decisions.

A secondary theory, design defect, is being pursued by a narrower subset of plaintiffs. That theory argues the drug's mechanism of action creates an unreasonably dangerous product regardless of labeling.

*Attorney Insight: Attorneys handling these claims point to internal Novo Nordisk clinical documents as the evidentiary core of the failure-to-warn theory, particularly data from pre-approval semaglutide trials that showed gastric emptying delays at therapeutic doses.*

Core Legal Theories in MDL 3094:

Wegovy Lawsuit 2026: Where the Case Stands

As of early 2026, the Wegovy lawsuit is in an active pretrial discovery phase within MDL No. 3094 in the Eastern District of Pennsylvania. No global settlement has been reached or announced.

Judge Karen S. Marston has issued several case management orders governing the pace of discovery, the structure of plaintiff fact sheets, and the process for identifying bellwether cases. Bellwether trials, the test cases used to gauge jury response before any broader settlement negotiation, are expected to be identified through 2026.

This phase is critical. In pharmaceutical mass torts of this size, the outcome of two or three bellwether trials typically determines the settlement range that both sides find acceptable. Opioid MDLs and the Zantac litigation followed that same structural arc.

*Attorney Insight: Attorneys handling these claims note that the plaintiff fact sheet process, now underway in MDL 3094, is not a formality. Incomplete or inconsistent fact sheets have caused cases to be dismissed in other pharmaceutical MDLs.*

2026 MDL 3094 Litigation Calendar (Estimated):

Wegovy Class Action Lawsuit: Is This a Class Action or a Mass Tort?

The Wegovy litigation operates on two structurally different legal tracks, and most coverage conflates them incorrectly.

The mass tort track handles individual personal injury claims. Each plaintiff's damages are evaluated separately based on their specific medical history, injury severity, treatment costs, and lost income. This track is where the gastroparesis, bowel obstruction, and pancreatitis cases sit. MDL consolidation is not a class action. It is an administrative tool that groups cases for pretrial efficiency while preserving individual plaintiff rights.

The class action track addresses consumer fraud and economic injury claims. These plaintiffs argue they paid a premium for a drug whose risks were misrepresented. If they can certify a class, members would share a settlement fund, likely receiving far smaller individual payments than personal injury claimants.

*Attorney Insight: Attorneys handling these claims consistently direct physically injured patients toward the personal injury mass tort track, not the class action track, because individual damage awards in proven failure-to-warn cases historically outperform class settlement distributions by a substantial margin.*

Mass Tort vs. Class Action: Key Differences

Wegovy Lawsuit Update: Latest Developments in 2026

The most significant 2026 development in MDL 3094 is the ongoing completion of the plaintiff fact sheet process, which is functioning as the first significant culling mechanism in the litigation.

Judge Marston has signaled, through case management orders, that the court expects rigorous documentation of both injury and Wegovy exposure. Cases lacking confirmed medical records linking semaglutide use to a diagnosed gastrointestinal condition face dismissal show-cause orders.

On the defense side, Novo Nordisk has argued in pretrial briefings that its FDA-approved labeling already included warnings about gastrointestinal adverse events, and that sophisticated prescribers, primarily endocrinologists and internists, were adequately informed. That argument is expected to be tested against plaintiff expert testimony on what "adequate warning" requires under federal pharmaceutical standards.

*Attorney Insight: Attorneys handling these claims note that Novo Nordisk's "sophisticated intermediary" defense is the same argument Merck deployed in early Vioxx litigation. In that case, the argument ultimately did not shield the company from liability once internal communications entered evidence.*

Key Defense Arguments vs. Plaintiff Responses:

Novo Nordisk Wegovy Lawsuit: Who Is Being Sued?

The named defendants in MDL No. 3094 are Novo Nordisk A/S, the Danish parent company, and its U.S. subsidiary, Novo Nordisk Inc., headquartered in Plainsboro, New Jersey.

Some earlier-filed state court complaints also named Eli Lilly and Company, the manufacturer of tirzepatide (Mounjaro/Zepbound), as a co-defendant under similar GLP-1 injury theories. As of early 2026, Lilly-related claims have largely been severed or separately docketed, keeping the MDL 3094 focus on Novo Nordisk's semaglutide products.

Wegovy and Ozempic are both semaglutide formulations manufactured by Novo Nordisk. Ozempic (1 mg dose) is FDA-approved for Type 2 diabetes. Wegovy (2.4 mg dose) is FDA-approved for chronic weight management. Both are named in the MDL because the injury pattern is consistent across both products.

*Attorney Insight: Attorneys handling these claims observe that plaintiffs who used Ozempic off-label for weight loss, rather than Wegovy specifically, may still have viable claims under MDL 3094, since both products share the same active compound and injury mechanism.*

Novo Nordisk Semaglutide Products in Litigation:

Wegovy MDL 3094: Understanding the Federal Consolidation

MDL No. 3094, formally titled *In re: Ozempic/Wegovy (Semaglutide) Products Liability Litigation*, was created by the Judicial Panel on Multidistrict Litigation on February 6, 2024.

The JPML selected the Eastern District of Pennsylvania as the transferee court, citing Philadelphia's established infrastructure for large pharmaceutical mass torts. The Eastern District of Pennsylvania previously handled portions of the Risperdal, Pradaxa, and mesh device litigations.

Judge Karen S. Marston was assigned as the presiding MDL judge. She has issued multiple case management orders establishing plaintiff fact sheet requirements, a science day for the court to receive expert briefings on GLP-1 pharmacology, and a structured bellwether selection protocol.

*Attorney Insight: Attorneys handling these claims regard the Eastern District of Pennsylvania as a plaintiff-leaning venue by historical pharmaceutical MDL standards, though Judge Marston has demonstrated a strong preference for procedural rigor that requires plaintiff firms to maintain complete and accurate case documentation.*

MDL 3094 Key Administrative Facts:

Litigation Watch: MDL No. 3094 is now in active pretrial discovery, the plaintiff fact sheet process is functioning as a case-quality filter, and the bellwether selection process now underway in 2026 will determine the settlement leverage available to both sides within the next 12 to 24 months.

Semaglutide Lawsuit: Why the Entire Drug Class Is Under Scrutiny

The Wegovy litigation did not arise in isolation. It is part of a broader legal examination of the entire GLP-1 receptor agonist drug class, which includes semaglutide, liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound).

The core pharmacological concern is GLP-1 receptors' role in slowing gastric motility, the rate at which food moves through the stomach and intestines. That mechanism is intentional and is partly responsible for the drugs' weight-loss effect. The legal question is whether the degree of motility slowing in some patients crosses from a therapeutic side effect into a serious, sometimes permanent injury.

FDA issued an updated label for semaglutide products in September 2023 to add ileus (bowel obstruction) as a listed adverse event. Plaintiffs argue that update proves Novo Nordisk's prior labeling was deficient. The company argues it acted within standard pharmacovigilance procedures.

*Attorney Insight: Attorneys handling these claims treat the September 2023 FDA labeling update as a pivotal evidentiary marker. Cases where plaintiffs were injured before that update, and were not warned of ileus risk, sit in a stronger failure-to-warn posture than cases arising after the revised label was in place.*

GLP-1 Drugs Currently Under Legal Scrutiny:

Wegovy Side Effects Lawsuit: The Medical Foundation of the Claims

The Wegovy side effects lawsuit rests on specific, diagnosed medical conditions, not general discomfort or mild nausea that resolved quickly.

The injuries at the center of MDL 3094 personal injury claims fall into four primary categories: gastroparesis, intestinal obstruction, cyclic vomiting syndrome, and pancreatitis. Each of these conditions requires a formal clinical diagnosis, typically confirmed through imaging, endoscopy, gastric emptying studies, or laboratory findings.

What distinguishes these injuries from the standard GI side effects listed on Wegovy's original label is severity and duration. Short-term nausea and vomiting are disclosed on the label. Permanent or near-permanent gastric paralysis requiring feeding tube placement is a categorically different harm.

*Attorney Insight: Attorneys handling these claims emphasize that the medical record chain must show a temporal link between semaglutide initiation and symptom onset. Cases where gastroparesis symptoms appeared weeks to months after starting Wegovy, with no prior GI history, present the cleanest causal picture for expert testimony.*

Core Medical Injuries in Wegovy Litigation:

Wegovy Gastroparesis Lawsuit: The Lead Injury Category

Gastroparesis is the most commonly alleged injury in Wegovy-related litigation, and it is the condition drawing the greatest attention from the plaintiff steering committee in MDL 3094.

Gastroparesis means the stomach muscles fail to move food into the small intestine at a normal rate. Severe cases result in chronic nausea, vomiting, weight loss beyond what is intended, malnutrition, and in the worst cases, the need for a surgically placed jejunostomy or gastrostomy tube to bypass normal feeding entirely.

The condition can be measured objectively through a gastric emptying scintigraphy study, a nuclear medicine test that tracks how quickly radiolabeled food clears the stomach. That objective measurability makes gastroparesis the most legally documentable of the four primary injury categories in this litigation.

Do not miss this: Drake UMG Lawsuit 2026: Claims, Court Status, Outcome

*Attorney Insight: Attorneys handling gastroparesis claims note that cases where the patient required hospital admission, specialized gastroenterology care, or tube feeding present the strongest damages profile. Cases involving only dietary modification and resolved symptoms within months may not meet the threshold that plaintiff firms are currently prioritizing in MDL 3094.*

Gastroparesis Severity Tiers and Litigation Relevance:

Wegovy Bowel Obstruction Lawsuit: The September 2023 FDA Label Change

The wegovy bowel obstruction lawsuit claims received a significant legal boost when the FDA required Novo Nordisk to add ileus to Wegovy's and Ozempic's prescribing information in September 2023.

Ileus is the medical term for a failure of normal intestinal movement, which can produce a functional bowel obstruction even without a physical blockage. A mechanical obstruction, where the bowel is physically blocked, is a separate but related condition also alleged in these cases. Both require urgent medical intervention, often hospitalization and sometimes surgery.

The September 2023 label change is significant because it was prompted by a signal identified in the FDA Adverse Event Reporting System (FAERS). That signal had existed, plaintiff experts argue, before the label was updated. The gap between when Novo Nordisk should have known and when it actually disclosed is a central element of the failure-to-warn timeline.

*Attorney Insight: Attorneys handling these claims specifically focus on the pre-September 2023 injury window. A patient who developed bowel obstruction in 2021 or 2022, before any ileus warning existed on the label, has a temporally cleaner failure-to-warn argument than one injured after the updated label was in circulation.*

Bowel Obstruction Claim Timeline:

Wegovy Pancreatitis Lawsuit: A Separate Injury Track

Pancreatitis claims in the Wegovy litigation travel on a partially distinct evidentiary track from gastroparesis and ileus claims, because pancreatitis risk has appeared on GLP-1 drug labels in some form since the class was introduced.

Early liraglutide and exenatide labels included warnings about pancreatitis risk. Semaglutide labels followed with similar language. Plaintiff attorneys in the pancreatitis sub-group are arguing that while pancreatitis was nominally mentioned, the severity and incidence rate disclosed were materially understated.

There is also a subgroup of cases involving acute necrotizing pancreatitis, the most severe form, where the pancreas suffers significant tissue death. These cases carry substantially higher damages potential given the severity of the injury and the long-term consequences for digestive function.

*Attorney Insight: Attorneys handling pancreatitis claims note that these cases often require a stronger causation expert than gastroparesis cases, because pancreatitis has multiple non-drug causes, including alcohol use and gallstones, that defense experts will aggressively argue as alternative explanations.*

Pancreatitis Claim Strength Factors:

• No prior history of pancreatitis before Wegovy use
• No heavy alcohol use or gallstone disease documented
• Onset within weeks to months of semaglutide initiation
• Acute pancreatitis confirmed by imaging and lab work
• Hospitalization or ICU care required
• Recurrent episodes during continued drug use

Litigation Watch: The three primary injury categories in MDL 3094, gastroparesis, bowel obstruction, and pancreatitis, each require distinct evidentiary chains, and the strength of any individual claim depends heavily on medical record completeness, pre-existing condition documentation, and the timing of injury onset relative to drug initiation.

Wegovy Lawsuit Who Qualifies: Eligibility Criteria

Qualifying for a Wegovy personal injury claim in MDL 3094 requires meeting a specific threshold of documented drug exposure, diagnosed injury, and causal connection.

Plaintiff firms active in this MDL have set internal intake criteria that generally require a formal diagnosis of one of the recognized injury categories, confirmed use of Wegovy or Ozempic, and a minimum level of injury severity. Most active plaintiff firms are currently focusing on cases requiring hospitalization or ongoing medical treatment, rather than injuries that resolved quickly with no lasting harm.

The checklist below reflects the general criteria plaintiff firms are applying. Individual firm thresholds may vary.

*Attorney Insight: Attorneys handling these claims note that off-label Ozempic users prescribed the drug for weight management, not diabetes, are treated the same as Wegovy users in terms of MDL eligibility, since the injury mechanism and the failure-to-warn theory are identical.*

General Wegovy Lawsuit Eligibility Criteria:

Who Generally Does NOT Qualify:

• Patients with only nausea or vomiting that resolved on its own
• Patients with a pre-existing diagnosis of gastroparesis before starting semaglutide
• Patients whose injuries were caused by a documented unrelated condition
• Patients outside the applicable statute of limitations window

Wegovy Personal Injury Claim: How the Legal Process Works

A Wegovy personal injury claim in MDL 3094 begins with the retention of a plaintiff attorney, typically a firm specializing in pharmaceutical mass torts.

After signing a representation agreement, the attorney files a short form complaint in MDL 3094 that links the plaintiff's case to the master complaint already on file. The plaintiff then completes a plaintiff fact sheet, a detailed questionnaire requiring medical records, prescription records, pharmacy records, and a written description of injuries and treatment.

These cases do not go to individual trial immediately. The MDL process requires all pretrial proceedings, including discovery, expert disclosure, and dispositive motions, to occur in the consolidated court in Philadelphia. Individual cases may eventually be remanded to their home district for trial, but that step is typically years away in large pharmaceutical MDLs.

*Attorney Insight: Attorneys handling these claims advise clients that the plaintiff fact sheet process is as important as the initial complaint. Errors or omissions on the fact sheet create vulnerabilities that defense counsel will exploit during depositions and at trial.*

Wegovy Personal Injury Claim Process:

1. Consult with a pharmaceutical litigation attorney
2. Sign representation agreement and gather medical records
3. Attorney files short form complaint in MDL 3094 (E.D. Pa.)
4. Complete plaintiff fact sheet with full documentation
5. Participate in discovery (depositions, medical record review)
6. Case evaluated for bellwether pool or settlement pool
7. Resolution via individual settlement or trial

Wegovy Settlement Amount: What Compensation May Look Like

No formal Wegovy settlement fund has been established as of early 2026. The litigation has not yet reached the stage where Novo Nordisk has entered substantive settlement negotiations on a global basis.

That said, the damages framework for individual cases is already being developed through the discovery and expert disclosure process. Pharmaceutical mass tort settlements typically include several categories of compensable harm.

Projecting settlement values at this stage requires reference to comparable pharmaceutical MDLs. The Xarelto settlement (2019, $775 million for approximately 25,000 claimants) averaged roughly $31,000 per case. The Valsartan settlement included amounts ranging from the low tens of thousands to over $1 million for cancer-linked claims. Wegovy cases involving permanent gastroparesis requiring tube feeding are categorically more severe than Xarelto bleeding cases in most damages assessments.

*Attorney Insight: Attorneys handling these claims caution that early global settlement projections carry significant uncertainty at this stage. Published estimates ranging from $150,000 to $500,000 for severe cases are framework figures based on comparable MDL outcomes, not confirmed Novo Nordisk offers.*

Potential Damages Categories in Wegovy Claims:

Wegovy Lawsuit Compensation: State-by-State Filing Considerations

Wegovy lawsuit compensation claims are filed federally within MDL 3094, but the underlying applicable state law, including the statute of limitations and available damages caps, varies by the plaintiff's home state.

This matters because some states cap non-economic damages (pain and suffering) in personal injury cases. States including California, New York, Texas, Florida, Pennsylvania, Ohio, and Illinois account for the largest plaintiff populations in pharmaceutical mass torts, both because of population density and because all took Wegovy at high prescription rates as the drug gained commercial momentum after its 2021 FDA approval.

Some states have a discovery rule for the statute of limitations, meaning the clock starts when the plaintiff knew or should have known about the injury's connection to the drug. Other states use a strict injury date. This distinction is material for patients who were injured in 2021 or 2022 but only recently connected their gastroparesis diagnosis to Wegovy.

*Attorney Insight: Attorneys handling these claims note that patients in states with strict statutes of limitations, without discovery rule protection, face the most urgent filing timeline pressure. A pharmaceutical litigation attorney in the plaintiff's home state can assess which limitations period applies.*

Statute of Limitations by Selected State:

Litigation Watch: Compensation amounts in MDL 3094 remain unconfirmed by any Novo Nordisk settlement offer, but the damages framework being built through expert discovery in 2026 will directly determine the settlement leverage plaintiffs hold when global negotiations eventually begin.

Wegovy Lawsuit Payout Per Person: Realistic Expectations

The Wegovy lawsuit payout per person cannot be stated with precision at this stage because no settlement has been reached and no bellwether trial has produced a jury verdict that anchors the damages range.

What can be assessed is the comparative framework. Pharmaceutical mass torts are tiered, typically placing cases into settlement bands based on injury severity, duration of treatment, medical costs, and the degree to which the plaintiff's evidence supports the core legal theories. Severe, permanent injury cases receive the highest tier awards.

Based on comparable mass tort structures, a rough damage-tier framework for Wegovy cases might look like the following. These figures are framework projections derived from comparable MDL history, not confirmed numbers from any Novo Nordisk communication.

Along the same lines: Shein Lawsuit 2026: Claims, Status and Who Qualifies

*Attorney Insight: Attorneys handling these claims note that punitive damages, while theoretically available if Novo Nordisk's internal communications show suppression of safety data, are rarely included in pharmaceutical MDL global settlements. They are more likely to emerge in individual bellwether verdicts that pressure the overall settlement negotiation.*

Projected Wegovy Compensation Tiers (Based on Comparable MDLs):

*Note: These figures are framework estimates derived from comparable pharmaceutical MDL outcomes. No Wegovy-specific settlement fund or tier matrix has been publicly established as of early 2026.*

Wegovy Lawsuit Filing Deadline: Statutes of Limitations in 2026

The Wegovy lawsuit filing deadline is not a single national date. Each plaintiff's deadline is governed by the statute of limitations in their home state, which typically runs from the date of injury or the date the plaintiff reasonably discovered the connection between the drug and their injury.

For patients who began using Wegovy in mid-2021, the initial FDA approval date, a two-year statute of limitations without discovery rule protection would theoretically have run by mid-2023. However, most states with a discovery rule, which includes California, Florida, Texas, and Pennsylvania, reset the clock from when the patient knew or should have known their injury was drug-related. Given that gastroparesis was not publicly discussed as a semaglutide risk until mid-to-late 2023, many 2021 and 2022 injury cases remain timely under the discovery rule.

The 2026 filing window remains open for many plaintiffs, but it is narrowing. Patients who have known about their injury and its potential connection to Wegovy for more than two years, without consulting an attorney, face genuine limitations risk.

*Attorney Insight: Attorneys handling these claims uniformly advise that consultation should occur before the statute of limitations question becomes dispositive. Timing analysis is case-specific, and no general timeline applies to every plaintiff in every state.*

Filing Deadline Risk Assessment:

How to Join the Wegovy Lawsuit: The Practical Steps

Joining the Wegovy lawsuit means retaining a plaintiff attorney who is actively handling pharmaceutical mass tort claims within MDL 3094. No government agency administers a public sign-up process.

The practical sequence is straightforward. A prospective plaintiff contacts a pharmaceutical litigation law firm. The firm conducts an intake call to assess eligibility based on drug use, diagnosis, and injury severity. If the case meets the firm's threshold, the attorney and client execute a contingency fee representation agreement, meaning the client pays no upfront legal fees. The firm then begins the process of gathering medical and prescription records before filing in the MDL.

Plaintiffs in MDL 3094 who are already represented do not need to re-file or take additional action beyond responding to their attorney's requests for documentation. The MDL structure handles the coordination.

*Attorney Insight: Attorneys handling these claims note that national pharmaceutical litigation firms with existing presence in MDL 3094, firms that have already obtained liaison counsel status or serve on the plaintiff steering committee, typically offer the most direct path to case activity, because they are already engaged in the discovery process.*

Documents to Gather Before Contacting an Attorney:

• Prescription records for Wegovy or Ozempic (pharmacy printout or patient portal records)
• Medical records documenting the qualifying diagnosis (gastroenterology notes, hospital records)
• Imaging reports (CT scans, gastric emptying study results)
• Records of emergency room or hospital admissions
• Records of any surgical procedures related to the GI injury
• Documentation of lost wages if applicable
• Any correspondence from Novo Nordisk, pharmacies, or insurers

Frequently Asked Questions

What is the Wegovy lawsuit about?

The Wegovy lawsuit alleges Novo Nordisk failed to adequately warn patients and physicians that semaglutide can cause serious gastrointestinal injuries, including gastroparesis, bowel obstruction, and pancreatitis.

The cases are consolidated in MDL No. 3094 before Judge Karen S. Marston in the Eastern District of Pennsylvania.

The core legal theory is failure to warn, with secondary claims of design defect and consumer fraud.

What is the current status of Wegovy litigation in 2026?

MDL 3094 is in the active pretrial discovery phase as of early 2026.

Plaintiff fact sheets are being completed, expert witnesses are being identified, and bellwether case selection is ongoing.

No global settlement has been announced.

Is there a Wegovy class action lawsuit or a mass tort?

Both exist, but they are separate tracks serving different types of plaintiffs.

The mass tort personal injury track, within MDL 3094, handles patients who suffered physical harm like gastroparesis or bowel obstruction.

The class action track handles economic or consumer fraud claims from patients who argue they were misled about the drug's safety profile.

What injuries qualify for a Wegovy lawsuit?

The qualifying injuries in MDL 3094 are gastroparesis, intestinal obstruction or ileus, cyclic vomiting syndrome, pancreatitis, and in some cases pulmonary aspiration.

Each must be confirmed by a formal medical diagnosis with supporting records.

Mild GI symptoms that resolved without significant treatment generally do not meet the current threshold applied by plaintiff firms.

How much is the Wegovy lawsuit settlement per person?

No settlement fund has been established as of early 2026.

Framework projections based on comparable pharmaceutical MDLs suggest a range from approximately $50,000 for moderate cases to $500,000 or more for severe, permanent injury cases.

Final values will not be determinable until bellwether verdicts establish the settlement leverage range.

What is the deadline to file a Wegovy lawsuit claim?

There is no single national deadline. Each plaintiff's filing deadline is set by the statute of limitations in their home state, typically two to three years from the date of injury or discovery.

Many states apply a discovery rule, meaning the clock runs from when the patient knew or should have known their injury was drug-related.

Given that gastroparesis and ileus were not widely publicized as semaglutide risks until late 2023, many plaintiffs injured in 2021 and 2022 may still be within the limitations period, but that window is closing in 2026.

Closing

MDL 3094 is at the stage where case-building matters most. The plaintiff fact sheet process, expert disclosures, and bellwether selection happening in 2026 will determine the settlement posture for thousands of claims.

Anyone who used Wegovy or Ozempic and was subsequently diagnosed with gastroparesis, bowel obstruction, pancreatitis, or a related serious gastrointestinal condition should treat this year as the operative moment for legal consultation. Statute of limitations deadlines are state-specific and are actively closing for patients injured in 2021 and 2022.

The right attorney for this case is one with active pharmaceutical mass tort experience and current presence within MDL 3094, not a general personal injury practitioner. The litigation infrastructure already exists. The question is whether a prospective plaintiff acts before their state's filing window closes.

For more context, see Select Home Warranty Lawsuit 2026: Full Case Guide